Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 9:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 100 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Natriuretic Peptides Clear all
Terminated Phase 4 Interventional Results available

Nesiritide and Renal Function After the Total Artificial Heart

NCT01836809
View directory record Official record
Conditions
Congestive Heart Failure, Cardiorenal Syndrome
Interventions
nesiritide, placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 8, 2016 · Synced Sep 30, 2026, 9:09 AM EDT
Active, not recruiting Phase 2 Interventional

An Extension Study to Evaluate Safety and Efficacy of BMN 111 in Children With Achondroplasia

NCT03989947
View directory record Official record
Conditions
Achondroplasia
Interventions
Active BMN 111: Subcutaneous injection of recommended dose of BMN 111 based on weight-band dosing once daily.
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
15 Months and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2038
U.S. locations
9
States / cities
Oakland, California • Torrance, California • Wilmington, Delaware + 6 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Sep 30, 2026, 9:09 AM EDT
Completed No phase listed Observational

C-Type Natriuretic Peptide and Achondroplasia

NCT01541306
View directory record Official record
Conditions
Achondroplasia, Hypochondroplasia
Interventions
Not listed
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
3 Months and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Wilmington, Delaware
Source: ClinicalTrials.gov public record
Updated Apr 14, 2015 · Synced Sep 30, 2026, 9:09 AM EDT
Completed Not applicable Interventional

Provider Notification for High B-type Natriuretic Peptide Values

NCT01734135
View directory record Official record
Conditions
Heart Failure
Interventions
Clinical Reminder
Other
Lead sponsor
VA Palo Alto Health Care System
Federal
Eligibility
18 Years to 120 Years
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 19, 2025 · Synced Sep 30, 2026, 9:09 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

PET Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With 64Cu-NODAGA-CANF (Volunteer - Dosimetry Study)

NCT07800481
View directory record Official record
Conditions
Healthy Adult, Healthy
Interventions
64Cu-NODAGA-CANF
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 30, 2026, 9:09 AM EDT
Completed Phase 2 Interventional

A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension

NCT06608901
View directory record Official record
Conditions
Sepsis-Induced Hypotension
Interventions
REGN7544, PB
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
16
States / cities
Tucson, Arizona • New Haven, Connecticut • Atlanta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Sep 30, 2026, 9:09 AM EDT
Completed Phase 3 Interventional

Brain Natriuretic Peptide (BNP) to Preserve Renal Function in Hospitalized Patients With Heart Failure

NCT00170183
View directory record Official record
Conditions
Kidney Diseases, Congestive Heart Failure, Cardiomyopathy
Interventions
Nesiritide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 16, 2009 · Synced Sep 30, 2026, 9:09 AM EDT
Terminated Phase 2 Interventional

REGN5381 in Adult Participants With Heart Failure With Reduced Ejection Fraction

NCT06237309
View directory record Official record
Conditions
Heart Failure
Interventions
REGN5381, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Phoenix, Arizona • Torrance, California • Miami, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 30, 2026, 9:09 AM EDT
Recruiting Phase 2Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia

NCT07441876
View directory record Official record
Conditions
Achondroplasia
Interventions
BMN 333, Vosoritide Injection [Voxzogo]
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
2 Years to 17 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
9
States / cities
Oakland, California • Wilmington, Delaware • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Sep 30, 2026, 9:09 AM EDT
Completed Phase 1 Interventional

CD-NP in Subjects With Stable Chronic Heart Failure

NCT00620308
View directory record Official record
Conditions
Stable Chronic Heart Failure
Interventions
CD-NP, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Sep 30, 2026, 9:09 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of BMN 111 in Children With Achondroplasia

NCT03197766
View directory record Official record
Conditions
Achondroplasia
Interventions
BMN 111, Placebo
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
5 Years to 18 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Oakland, California • Torrance, California • Wilmington, Delaware + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Sep 30, 2026, 9:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Natriuretic Peptide System in African-Americans.

NCT02730780
View directory record Official record
Conditions
Healthy, Prehypertension
Interventions
Low-Salt Diet, High-Salt Diet
Dietary Supplement
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 9, 2022 · Synced Sep 30, 2026, 9:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Comparison of BNP Levels Using the Nexfin Device in Healthy Pregnant and Preeclamptic Women

NCT02527018
View directory record Official record
Conditions
Preeclampsia, Maternal, Hypertension, Pregnancy
Interventions
Sphygmomanometer
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2018 · Synced Sep 30, 2026, 9:09 AM EDT
Completed Phase 2 Interventional

Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)

NCT06593600
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome (POTS)
Interventions
REGN7544, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
15
States / cities
Gilbert, Arizona • Carlsbad, California • Palo Alto, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 30, 2026, 9:09 AM EDT
Terminated Phase 2 Interventional Results available

A Study of Ponsegromab in People With Heart Failure

NCT05492500
View directory record Official record
Conditions
Heart Failure
Interventions
Main cohort (Cohort A): Ponsegromab low dose, Main cohort (Cohort A): Ponsegromab medium dose, Main cohort (Cohort A): ponsegromab high dose, Main cohort (Cohort A): Matched placebo, Open-label, PK Cohort (Cohort B): ponsegromab low dose, Open-label, PK Cohort (Cohort B): ponsegromab medium dose, Open-label, PK Cohort (Cohort B): ponsegromab high dose, Optional Cohort C: Ponsegromab low dose, Optional Cohort C: Matched placebo, Optional Cohort D: Ponsegromab high dose, Optional Cohort D: Matched placebo
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
22
States / cities
Fairhope, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 30, 2026, 9:09 AM EDT
Completed No phase listed Observational

Utility of Serial BNP Levels in Emergency Department CHF

NCT00534066
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2007 · Synced Sep 30, 2026, 9:09 AM EDT
Completed No phase listed Observational

Measurement of Natriuretic Hormone Peptides in Exacerbation of Asthma

NCT01690793
View directory record Official record
Conditions
ASTHMA
Interventions
Not listed
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated May 28, 2015 · Synced Sep 30, 2026, 9:09 AM EDT
Completed No phase listed Observational

Access Natriuretic Peptide Assay(s) Pivotal - Emergency Department Subject Enrollment and Specimen Collection

NCT04169815
View directory record Official record
Conditions
Heart Failure
Interventions
Access Immunodiagnostic Products
Diagnostic Test
Lead sponsor
Beckman Coulter, Inc.
Industry
Eligibility
21 Years and older
Enrollment
2,370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
15
States / cities
Loma Linda, California • Sacramento, California • Gainesville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Sep 30, 2026, 9:09 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Genetic Architecture of Natriuretic Peptides and Blood Pressure Response

NCT07118592
View directory record Official record
Conditions
Hypertension (HTN), Cardiometabolic Diseases
Interventions
Low Salt Diet, High Salt Diet, Saline Infusion
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 30, 2026, 9:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Do Elevated BNP Levels Predict Hemodynamically Significant PDAs

NCT01497054
View directory record Official record
Conditions
Patent Ductus Arteriosus
Interventions
Not listed
Lead sponsor
Albany Medical College
Other
Eligibility
1 Hour to 24 Hours
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2013 · Synced Sep 30, 2026, 9:09 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Beige Fat, Energy, and the Natriuretic Peptide System

NCT04357964
View directory record Official record
Conditions
Obesity
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 55 Years
Enrollment
137 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 1, 2024 · Synced Sep 30, 2026, 9:09 AM EDT
Completed No phase listed Observational

B-type Natriuretic Peptide in the Non-Cardiac Pediatric Patient

NCT00330811
View directory record Official record
Conditions
Heart Diseases
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
1 Day to 5 Years
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 2, 2016 · Synced Sep 30, 2026, 9:09 AM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis

NCT04971720
View directory record Official record
Conditions
Obesity, Cardiovascular Diseases, Hypertension, Nocturnal Blood Pressure, Natriuretic Peptides, Renin-Angiotensin-Aldosterone System
Interventions
Sacubitril-Valsartan 49 Mg-51 Mg Oral Tablet, Valsartan 80 mg Oral Tablet
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Sep 30, 2026, 9:09 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

PET Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis (Volunteer - BioD and Safety Study)

NCT02498379
View directory record Official record
Conditions
Atherosclerosis
Interventions
Cu[64]-25%CANF-Comb
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
21 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Sep 30, 2026, 9:09 AM EDT